The U.S. Biopharmaceuticals Contract Manufacturing Market was valued at USD 10.67 Billion in 2024, and is projected to reach USD 19.54 Billion by 2030, rising at a CAGR of 10.60%. The market is growing due to the rising demand for biologics and biosimilars, which address complex diseases with innovative therapies. Advancements in manufacturing technologies, such as single-use systems and continuous processing, enhance production efficiency and scalability. These factors enable contract manufacturers to meet the rising need for cost-effective and high-quality biopharmaceuticals, driving market growth and fostering innovation in the industry.
The market thrives due to a focus on cost-effective production and the expansion of Contract Manufacturing Organizations (CMOs). By outsourcing manufacturing, companies reduce operational costs and allocate resources for innovation. CMOs provide scalable solutions, advanced technologies, and specialized expertise, ensuring efficient production. Their growth enables biopharma companies to meet the rising demand for biologics and biosimilars, driving market expansion and fostering innovation in industry.
The growing prevalence of chronic diseases fuels the demand for advanced biopharmaceuticals, including biologics and biosimilars, to address complex health challenges. Simultaneously, technological innovations in bioprocessing, such as single-use systems and continuous manufacturing, are revolutionizing production efficiency and scalability. These advancements empower contract manufacturers to meet the rising need for high-quality, cost-effective therapies and contribute significantly to the growth and evolution of the biopharmaceutical industry in the U.S.
This product will be delivered within 1-3 business days.
The market thrives due to a focus on cost-effective production and the expansion of Contract Manufacturing Organizations (CMOs). By outsourcing manufacturing, companies reduce operational costs and allocate resources for innovation. CMOs provide scalable solutions, advanced technologies, and specialized expertise, ensuring efficient production. Their growth enables biopharma companies to meet the rising demand for biologics and biosimilars, driving market expansion and fostering innovation in industry.
The growing prevalence of chronic diseases fuels the demand for advanced biopharmaceuticals, including biologics and biosimilars, to address complex health challenges. Simultaneously, technological innovations in bioprocessing, such as single-use systems and continuous manufacturing, are revolutionizing production efficiency and scalability. These advancements empower contract manufacturers to meet the rising need for high-quality, cost-effective therapies and contribute significantly to the growth and evolution of the biopharmaceutical industry in the U.S.
U.S. Biopharmaceuticals Contract Manufacturing Market Report Highlights
- By source, the mammalian segment held the largest share in 2024, owing toits critical role in producing biologics like monoclonal antibodies and recombinant proteins.
- By service, the process development segment led the market with the largest revenue share of 34.8% in 2024, driven byits pivotal role in optimizing production efficiency and ensuring regulatory compliance.
- Theanalytical & QC studies segment is set to grow at the fastest CAGR over the forecast period, fueled bythe increasing need for stringent quality assurance and regulatory compliance in biopharmaceutical production.
- By products, the biologics segment dominated the market with the largest share in 2024 due toincreasing demand for advanced therapies like monoclonal antibodies, cell and gene therapies, and biosimilars.
- The biosimilars segment is projected to be the fastest-growing segment from 2025 to 2030, attributed to increasing demand for cost-effective alternatives to biologics.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Biopharmaceuticals Contract Manufacturing Market Variables, Trends, & Scope
Chapter 4. U.S. Biopharmaceuticals Contract Manufacturing Market: Source Business Analysis
Chapter 5. U.S. Biopharmaceuticals Contract Manufacturing Market: Service Business Analysis
Chapter 6. U.S. Biopharmaceuticals Contract Manufacturing Market: Products Business Analysis
Chapter 7. U.S. Biopharmaceuticals Contract Manufacturing Market: Type Business Analysis
Chapter 8. U.S. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Business Analysis
Chapter 9. U.S. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Business Analysis
Chapter 10. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this U.S. Biopharmaceuticals Contract Manufacturing market report include:- Lonza
- WuXi Biologics
- FUJIFILM Diosynth Biotechnologies
- Boehringer Ingelheim International GmbH
- Thermo Fisher Scientific Inc.
- Samsung Biologics
- AGC Biologics
- Catalent, Inc
- Rentschler Biopharma SE
- Eurofins Scientific
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 10.67 Billion |
| Forecasted Market Value ( USD | $ 19.54 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
